Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing pharmacokinetic, experimental, and clinical literature without systematic review methodology.
PubMed 27930973 · doi:10.1016/j.biopha.2016.11.098
What was done
This review examined published literature on the pharmacokinetics, physicochemical properties, experimental pharmacology, and clinical applications of phytosomal curcumin (curcumin complexed with phosphatidylcholine) for various human diseases.
What was found
The abstract provides no numerical data, effect sizes, or counts of analyzed studies. It qualitatively reports that phytosomal formulation improves the oral bioavailability and dispersion of curcumin in both hydrophilic and lipophilic media, and notes reported efficacy and safety in cancer, osteoarthritis, diabetic microangiopathy and retinopathy, and inflammatory diseases.
Why it matters
Formulating curcumin into a phospholipid complex addresses its severe pharmacokinetic limitations, including poor water solubility, instability at physiological pH, and rapid metabolism.
Limits
The paper is a narrative review rather than a systematic review or meta-analysis; no search strategy, inclusion criteria, or risk-of-bias assessments are described. The abstract lacks quantitative metrics, sample sizes, and specific clinical endpoints.
Cited by
- context Phytosomal delivery improves the bioavailability of curcumin by slowing its rapid hepatic clearance and metabolism.